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Abstract
Background: To test and compare in a masked fashion the efficacy of using a parasympathomimetic drug
(3% carbachol) and an alpha-2 agonist (0.2% brimonidine) in both combined and separate forms to create
optically beneficial miosis to pharmacologically improve vision in presbyopia.
Methods: A prospective, double-masked, randomized, controlled clinical trial was conducted. Ten naturally
emmetropic and presbyopic subjects between 42 and 58 years old with uncorrected distance visual acuity of
at least 20/20 in both eyes without additional ocular pathology were eligible for inclusion. All subjects received 3%
carbachol and 0.2% brimonidine in both combined and separate forms, 3% carbachol alone and 0.2% brimonidine
(control) alone in their non-dominant eye in a crossover manner with one week washout between tests. The subjects’
pupil sizes and both near and distance visual acuities will be evaluated pre- and post-treatment at 1, 2, 4, and 8 h,
by a masked examiner at the same room illumination.
Results: Statistically significant improvement in mean near visual acuity (NVA) was achieved in all subjects who
received combined 3% carbachol and 0.2% brimonidine in the same formula compared with those who received
separate forms or carbachol alone or brimonidine alone (P < 0.0001).
Conclusion: Based on the data, the combined solution demonstrated greater efficacy than the other solutions
that were tested. Improving the depth of focus by making the pupil small caused statistically significant improvement
in near visual acuity, with no change in binocular distance vision.
Trial registration: ACTRN12616001565437. Registered 11 November 2016.
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Background
Presbyopia is the age-related decline in accommodation
that diminishes the ability of the eye to focus on near
objects [1, 2]. This process usually becomes perceptible
between ages 40 and 50 and accelerates with age, neces-
sitating the application of corrective lenses in order to
restore near vision [3]. From a pathophysiologic stand-
point, multiple theories have been put forth in an attempt
to explain this decline in amplitude of accommodation.
Changes in the shape, size, and mechanical characteristics
of the lens, as well as the function of the ciliary muscle,
have all been described [4, 5]. Near visual acuity can be
improved by increasing the depth of focus as well as
accommodation. A variety of surgical procedures have
been considered for restoring accommodation to the pres-
byopic eye, including surgical expansion of the sclera,
using femtosecond lasers to treat the lens or with so-
called accommodative intraocular lenses (IOLs) [6]. For
accommodation to be restored to the presbyopic eye, it is
necessary that the ciliary muscle should still be able to
contract with an accommodative effort. There are several
lines of evidence that suggest that the ciliary muscle does
not atrophy with increasing age and does remain func-
tional; there is no age-related loss of contractility of the
isolated rhesus monkey ciliary muscle [7]. Similarly, when
the presbyopic eye makes an effort to accommodate, the
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ciliary muscle contracts [8, 9] despite the fact that the lens
shows no accommodative change [9]. Furthermore, the
ciliary muscle continues to contract with an accommoda-
tive effort even in the pseudophakic eye [10]. Increased
depth of focus can come from making the pupil smaller
much like a smaller aperture in a camera. The traditional
ways for improving vision in presbyopes was through in-
vasive procedures or wearing corrective lenses including
pinhole spectacles. Different approaches on the cornea
(inlays), the crystalline lens and the sclera are being pur-
sued to achieve surgical correction of this disability [6].
The KAMRA (AcuFocus, Irvine, California, USA) corneal
inlay is an annular aperture inlaid in the cornea of one eye
where a small entrance pupil is exploited to create a
pinhole-type effect that increases the depth of focus and
enables improvement in near visual acuity [11–16]. It also
reduces the amount of light entering the eye, so the inter-
ocular difference in retinal illuminance could alter per-
ceived depth via the Pulfrich effect [17]. Plainis et al.
concluded that the Pulfrich effect was not reduced by
adaptation, perhaps because the natural pupil diameter of
the dominant eye is continually changing throughout the
day due to varying illumination and other factors, making
adaptation difficult [18]. On the contrary, Ravikumar and
Banks [19] concluded that there was some evidence that
the KAMRA group experienced a small Pulfrich effect,
but the simulated-inlay group experienced a larger and
more consistent effect. Thus, KAMRA subjects ap-
peared to have adapted to the reduced illuminance in
the treated eye.
We attempted to use drops to approach this effect
without surgery. Topical treatment of presbyopia is an
attractive approach which, if available and effective,
would be the treatment of choice for many patients.
Carbachol stimulates the muscarinic and nicotinic re-
ceptors on the iris sphincter muscle to create miosis
resulting in a smaller pupil aperture that increases the
depth of focus. Brimonidine binds to Alpha-2 receptors
that are located on the presynaptic nerve endings of
the dilator muscle. This binding inhibits further
release of the neurotransmitter into the synaptic cleft.
This causes reduced activity of the dilator muscle and
thereby producing a more miotic pupil. This pilot
study aimed to test and compare the efficacy of using
a parasympathomimetic drug (3% carbachol) and an
alpha agonist (0.2% brimonidine) in both combined
and separate forms and individually to create optically
beneficial miosis to pharmacologically improve vision
in presbyopia.
Methods
This study was approved by the RCRC Independent
Review Board, Austin, Texas, as well as the Ethics Com-
mittee of Eye Center and Research, Aseer, Saudi Arabia.
Each participant gave written informed consent and the
study followed the tenets of the Declaration of Helsinki.
The pharmacological stimulation protocol was developed
in accordance with that used previously in the invention
of Dr. Herbert Kaufman [20].
Participants were randomly selected volunteers. Pres-
byopia was considered present if an uncorrected end-
point print size ≥ Jaeger (J) 5 improved by ≥ 1 optotype
with the use of a lens ≥ +1.00 D. All subjects were
screened to be in good physical and ocular health and
they completed a questionnaire to ascertain any contra-
indications for participation or predisposition to complica-
tions (e.g., heart or respiratory conditions, migraines,
high myopia, ocular or systemic medications, or ocular
surgeries). All subjects had a fully dilated eye examina-
tion before they were considered eligible for the study.
The examination screened for contraindications to the
drugs, susceptibility to retinal detachment, ocular patho-
logy, or peripheral retinal degeneration. Inclusion criteria
were as follows: age between 42 and 58 years, emmetropia
[cycloplegic spherical equivalent (SE), ± 0.25 D; astigma-
tism, ≤ 0.25 D] and binocular uncorrected distance visual
acuity ≥ 20/20. Exclusion criteria included patients with
myopia, hyperopia and astigmatism higher than 0.25 D as
well as those with corneal, lens and vitreous opacities,
pupil irregularities, anisocoria, amblyopia, chronic general
pathologies and medications that would interact unfavor-
ably with carbachol and brimonidine. None of the patients
included in the study had received any topical medication
that could cause pupil mydriasis or miosis. During the
study, the subjects were closely monitored and regularly
asked to report on any ocular, systemic, or physiological
reactions they experienced. Atropine was available in the
event of adverse effects, although none was reported.
All procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation.
Procedures
A single dose of 3% carbachol together with 0.2% brimo-
nidine in both combined and separate forms and 3%
carbachol alone or 0.2% brimonidine alone (control)
were instilled in the non-dominant eye of the same ten
emmetropic presbyopic subjects with one week washout
between tests. In the separate form, carbachol was in-
stilled first followed by brimonidine after 5 min. All of
the drugs administered in this study are approved by the
US Food and Drug Administration and have been used
for years as safe and effective agents for treating ocular
pathologies [21–24]. Initial pupil size and both near and
distance visual acuities were documented before treatment
and at 1, 2, 4, and 8 h after treatment by the same inde-
pendent examiner in the same room with the same instru-
ments. Distance visual acuity was measured using the
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standard Snellen projector chart at 4 m. Near visual acuity
(NVA) was assessed at 40 cm using a hand-held Rosen-
baum chart with Jaeger notation, always employing the
same luminosity of 160 cd/m2. Pupil size (PS) was mea-
sured using Colvard handheld Infrared pupillometer
(Oasis Medical, Glendora, CA, USA). Any adverse
symptoms and subject satisfaction with near and dis-
tance vision were also monitored.
Statistical analysis
Data analysis was carried out with the Mann-Whitney U
test, using the MedCalc version 16.8 statistical software.
A P value of less than 0.05 was considered statistically
significant. Data were expressed as mean, range, and
standard deviation (SD).
Results
Ten naturally emmetropic and presbyopic subjects with
a mean age of 49.7 ± 4.8 years (range, 42–58 years)
were eligible for inclusion. These subjects (6 males and
4 females) with an uncorrected distance visual acuity of
at least 20/20 in both eyes were without additional ocular
pathology.
In the combined drops group, the mean near visual
acuity (NVA) improved significantly from J 8.6 ± 1.5
before treatment to J 1.1 ± 0.3 at 1 h, J 1.1 ± 0.3 at 2 h, J
1.8 ± 0.4 at 4 h and J 2.3 ± 0.5 at 8 h post-treatment (P <
0.0001). The mean pupil size (PS) decreased significantly
from 4.3 ± 0.5 mm before treatment to 1.2 ± 0.3 mm at 1 h,
1.2 ± 0.3 mm at 2 h, 1.7 ± 0.2 mm at 4 h and 2.1 ± 0.3 mm
at 8 h post-treatment (P < 0.0001).
In the separate drops group, the mean NVA im-
proved significantly from J 8.6 ± 1.5 before treatment to J
3.4 ± 1 at 1 h (P = 0.0002), J 3.6 ± 1 at 2 h (P = 0.0002), J
4.5 ± 1 at 4 h (P = 0.0004) and J 5.2 ± 0.8 at 8 h (P =
0.0008) post-treatment. The mean (PS) decreased sig-
nificantly from 4.3 ± 0.5 mm before treatment to 1.9 ±
0.3 mm at 1 h, 2.2 ± 0.2 mm at 2 h, 2.5 ± 0.3 mm at 4 h and
2.8 ± 0.2 mm at 8 h post-treatment (P < 0.0001).
In the 3% carbachol alone group, the mean NVA im-
proved significantly from J 8.6 ± 1.5 before treatment to
J 5.5 ± 1 at 1 h (P = 0.001), J 5.9 ± 0.8 at 2 h (P = 0.001),
J 7 ± 1.2 at 4 h (P = 0.007) and J 7.5 ± 1 at 8 h (P
=0.027). The mean (PS) decreased significantly from
4.3 ± 0.5 mm before treatment to 2.8 ± 0.3 mm at 1 h
(P = 0.0002), 3 ± 0.3 mm at 2 h (P = 0.0002), 3.5 ±
0.3 mm at 4 h (P = 0.0007). At 8 h post-treatment,
mean (PS) was 4 ± 0.3 mm (P = 0.15).
In the 0.2% brimonidine alone group, no statistically
significant difference in mean NVA and mean (PS) was
found before treatment and at any time point after treat-
ment (P > 0.05).
Significant improvement in mean NVA was reported
in combined 3% carbachol and brimonidine drops than
separate forms or carbachol alone or brimonidine alone
(P < 0.0001).
Data are summarized in Table 1. Figures 1 and 2 show
the mean change in near visual acuity (Jaeger) and pupil
size (mm) over time for treatment and control groups.
Mild burning sensation was reported in one out of 10
subjects (10%) of the combined drops group compared
to 6 subjects (60%) when carbachol drops alone was
instilled. Three subjects (30%) in both brimonidine and
separate groups reported mild burning sensation. No
subject complained of the Pulfrich effect. All subjects in
our pilot study reported that they could drive safely day
and night without distortions in the perception of any
movement.
Table 1 Mean change in near visual acuity (NVA) (Jaeger) and pupil size (PS) (mm) over time for the same presbyopic subjects
receiving combined versus separate 3% carbachol plus 0.2% brimonidine, 0.2% brimonidine alone and 3% carbachol alone











Pre-treatment NVA (J) 8.6 ± 1.5 8.6 ± 1.5 8.6 ± 1.5 8.6 ± 1.5 1 1 1
PS (mm) 4.3 ± 0.5 4.3 ± 0.5 4.3 ± 0.5 4.3 ± 0.5 1 1 1
1-h NVA (J) 1.1 ± 0.3 3.4 ± 1 5.5 ± 1 7.7 ± 1.3 P < 0.0001 P < 0.0001 P < 0.0001
PS (mm) 1.2 ± 0.3 1.9 ± 0.3 2.8 ± 0.3 3.95 ± 0.5 P = 0.0006 P < 0.0001 P < 0.0001
2-h NVA (J) 1.1 ± 0.3 3.6 ± 1 5.9 ± 0.8 8.2 ± 1.3 P < 0.0001 P < 0.0001 P < 0.0001
PS (mm) 1.2 ± 0.3 2.2 ± 0.2 3 ± 0.3 4.2 ± 0.4 P < 0.0001 P < 0.0001 P < 0.0001
4-h NVA (J) 1.8 ± 0.4 4.5 ± 1 7 ± 1.2 8.5 ± 1.4 P < 0.0001 P < 0.0001 P < 0.0001
PS (mm) 1.7 ± 0.2 2.5 ± 0.3 3.5 ± 0.3 4.3 ± 0.5 P < 0.0001 P < 0.0001 P < 0.0001
8-h NVA (J) 2.3 ± 0.5 5.2 ± 0.8 7.5 ± 1 8.6 ± 1.5 P < 0.0001 P < 0.0001 P < 0.0001
PS (mm) 2.1 ± 0.3 2.8 ± 0.2 4 ± 0.3 4.3 ± 0.5 P = 0.0006 P < 0.0001 P < 0.0001
NVA = near visual acuity; PS = pupil size
*Level of statistical significance: P < 0.05
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Distance visual acuity
The uncorrected distance visual acuity was 20/20 of
both eyes in all subjects before treatment and remained
at 20/20 at all time periods after treatment in all groups.
Discussion
This study piloted a simple maneuver aimed at improving
near vision in presbyopic subjects. Rather than tackling
presbyopia with multifocal or accommodating lenses;
pharmacologic treatment relies on the pinhole effect –
increasing depth of focus by reducing aperture. The
principle is being successfully applied in corneal inlays
implanted in the non-dominant eye to enhance near
vision. The AcuFocus implant [11] is a corneal implant
with a small central artificial pupil. It restores reading
vision through increased depth of focus. Although there
are some problems with centering the implant i.e., the
Pulfrich effect and some surgical complications, it is
clear that the principle of a small pupil that moves with
the eye can give a good near vision and preserve dis-
tance acuity as well [16, 25, 26]. We attempted with
drops to approach this effect without surgical interference.
In our study, no subject complained of the Pulfrich effect,
which occurs due to intraocular differences in retinal
illuminance induced by anisocoria. All subjects in our
pilot study reported that they could drive safely day and
night without distortions in the perception of any
movement. However, the Pulfrich effect might have oc-
curred, but that was not objectively tested in this study.
In the event that the Pulfrich effect occurs and bothers
any subject, they can simply stop taking the drops un-
like other surgical procedures that necessitates reversal
of the procedure with possible operative and postopera-
tive complications.
In a previous study, a single dose of 2.25% carbachol
plus 0.2% brimonidine eye drops was used separately to
treat presbyopia and the subjects were followed up for
3 months with no reported ocular complications or
tachyphylaxis [27]. The present study used a higher
concentration of carbachol (3%) and an alpha agonist
(0.2% brimonidine) in both combined and separate
forms and individually to improve vision in presbyopia
through increasing the depth of focus. Significant im-
provement in near visual acuity was found to be higher
in all subjects who received combined 3% carbachol
and brimonidine in the same formula compared with
those who received separate forms or carbachol alone
or brimonidine alone (P < 0.0001). Carbachol, which is
Fig. 1 Distribution of mean change in near visual acuity (Jaeger) over time for treatment and control groups
Fig. 2 Distribution of mean change in pupil size (mm) over time for treatment and control groups
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formed by substituting a terminal amino group in the
acetylcholine molecule, is a quaternary ammonium com-
pound, and so has the pharmacological characteristics of
being lipid insoluble, surface inactive, and hydrophilic.
Carbachol, therefore, penetrates the cornea very poorly.
Corneal penetration by carbachol may be enhanced prac-
tically either by reducing the surface tension using ben-
zalkonium chloride as a wetting agent or by administering
it in a petrolatum-based ointment and massaging the cor-
nea through closed lids [28]. We attribute this marked
improvement in near visual acuity in subjects receiving
the combined formula to the penetration enhancers
(benzalkonium chloride and carboxymethylcellulose) that
were added to the combined formula and perhaps also to
the fact that when the receptors of iris dilator and con-
strictor muscles are both acted upon at the same time,
they reinforce each other than when one is stimulated
before the other permitting maximal effect with less to
overcome. Our results showed that brimonidine tartrate
0.2% alone produced a mild miotic effect mainly during
the first hour after instillation under light luminance
conditions but this did not reach statistical significance
(P > 0.05). The effect was similar to that reported in
other studies [29, 30]. On the other hand, other studies
reported that the antimydriatic effect of brimonidine
was pronounced under both light and dark luminance
conditions [31–34]. Therefore, the application of bri-
monidine 20 min before activities in dimly lit areas or
at night may be recommended for photic phenomena
following laser refractive surgery [35]. In monocular
treatment, the vision in the fellow eye with the normal
pupil will have some blurry near vision, but distant ob-
jects are clear and there is no diminished light percep-
tion. When the images are merged, all subjects of
treatment group had clear focus at near and distance
with no perception of dimness. Carbachol and brimoni-
dine can be used once daily to achieve an 8-h effect.
Conclusion
The monocular pharmacologic treatment of presbyopia
with one drop a day of carbachol and brimonidine in the
non-dominant eye permits acceptable reading vision for
many presbyopes even in older subjects. This topical
agent is noninvasive and, we believe, it meets all of the
criteria for an ideal treatment of presbyopia. Based on
the data, the combined solution demonstrated greater
efficacy than the other solutions that were tested. Despite
the small number and the heterogeneity of the patients
involved in this pilot study, its findings suggest that this
treatment is very promising. Additional studies are
planned in the future to use the drops in presbyopia
with different refractive errors as in hyperopic and
myopic presbyopes and in different situations such as
pseudophakic and postlasik presbyopes.
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